CA-TORAY-ADVANCED
8.12.2020 15:02:08 CET | Business Wire | Press release
Toray Advanced Composites announces that it has completed a long-term supply agreement with Joby Aviation for the composite material used for its aircraft. The California-based aircraft company will use Toray’s carbon fiber composite materials to bring fast, affordable, and zero-emissions aerial ridesharing to global communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005035/en/
Electric aircraft require proven materials that have high-strength and are very lightweight. Carbon fiber composite materials provide the strength-to-weight ratio needed for electric aerospace applications in order to maximize the range and speed of the aircraft. Every aspect of Joby’s aircraft is being optimized for maximum utilization for urban transport and high-quality carbon fiber materials are a key component of achieving their goals. Joby selected Toray Advanced Composite materials due to their proven heritage of meeting mechanical and safety requirements in aerospace and high-performance automotive applications.
JoeBen Bevirt, Founder and CEO, Joby Aviation, said: "Toray’s prepreg carbon fiber systems provide unparalleled specific strength and toughness, which have enabled Joby to develop aircraft with unprecedented capabilities. We are incredibly proud to be working with Toray as we certify this aircraft, and look forward to building a long-lasting partnership."
Joby will operate an affordable, quiet, and clean transportation service, using the revolutionary all-electric, vertical take-off and landing aircraft it has spent the last decade developing. With a range of up to 150 miles and a top speed of 200 mph, the vehicle and the service has the potential to make a significant difference to the lives of travelers. Carbon fiber materials are used throughout the vehicle structure, propulsion systems, and interior components.
“We are very pleased to have finalized this important supply agreement with Joby Aviation, a pioneer in the development of the eVTOL,” says Mr. Toshiyuki Kondo, CEO, Toray Advanced Composites. “As children, we dreamed of being able to fly to a destination in a fraction of the time it would take to drive. That is no longer a fantasy. The electric air taxi is becoming a reality and we at Toray are perfectly positioned to meet the industry’s needs today and in the future. It’s a very exciting time.”
Joby Aviation has spent more than a decade developing its aircraft and plans to bring it into commercial operation as early as 2023. By combining years of development with a world-class team and now a leading carbon fiber composite supplier, Joby is well-positioned to deliver on the promise of aerial ridesharing.
About Joby Aviation
Joby Aviation is a California-based aerospace company that is developing and commercializing all-electric vertical take-off and landing aircraft (designated by the FAA as the S4) to enable the deployment of fast, quiet, and affordable air taxi services. The company’s mission is to deliver people to their destination five times faster than driving would, reduce urban congestion, and accelerate the shift to sustainable modes of transit. Founded in 2009, Joby pioneered the development of eVTOL aircraft and has offices in Santa Cruz, San Carlos, and Marina, California. Find more information at http://www.jobyaviation.com
.
About Toray Advanced Composites
Toray Advanced Composites is a leader in the development and production of advanced thermoplastic and thermoset composite materials. The broad product portfolio is incorporated in high performance products for aerospace, space, communications, automotive, consumer, and industrial applications. Toray Advanced Composites has a long heritage of combining state-of-the-art materials technology with world-class technical expertise to deliver a unique customer-centric business model. Production and operation facilities are in North America, Europe, and Asia. Toray Advanced Composites is a subsidiary of the Toray Group. For more information visit, www.toraytac.com
©2020 Toray Advanced Composites. All trademarks are the property of Toray Industries Inc. unless otherwise stated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom